This study investigated the acute (within 24 hours) effect of the first administration of luseogliflozin, an SGLT2 inhibitor, on nocturnal basal GV in patients with type 2 diabetes mellitus. Here, SLC5A2 is linked to type 2 diabetes mellitus.